CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
ghrelindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01833078
NCT01833078Phase 2Completed
CompareCT.gov

Ghrelin in Frail Elderly Subcutaneous Repeated Dose Study

University of Pennsylvania·interventional·Posted Apr 16, 2013·Updated Oct 8, 2015

In Brief

A Phase 2 clinical trial evaluating ghrelin for Frailty in Aging. Completed, enrolled 5 participants across 1 site.

Detailed Summary

Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The investigators already know that a single dose of Ghrelin improves food intake immediately after the dose in frail older people. In this study, the investigators are trying to find out if repeated daily doses of ghrelin will help frail older people improve food intake for multiple days in a row.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrailty in Aging
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2013
Enrollment StartFeb 1, 2013
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.2 years ago

Interventions

ghrelindrug

ghrelin administration subcutaneously for 7 days